Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.

Mehdi Hamadani; Yuliya Linhares; Mitul Gandhi; Michael Chung; Helena Adamis; David Ungar; Carmelo Carlo-Stella

doi:10.1200/JCO.2021.39.15_SUPPL.TPS7574

Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.

Mehdi Hamadani, Yuliya Linhares, Mitul Gandhi, Michael Chung, Helena Adamis, David Ungar, Carmelo Carlo-Stella

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.TPS7574
State	Published - May 20 2021

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2021.39.15_SUPPL.TPS7574License: Unspecified

Cite this

Hamadani, M., Linhares, Y., Gandhi, M., Chung, M., Adamis, H., Ungar, D., & Carlo-Stella, C. (2021). Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5. Journal of Clinical Oncology, 39. https://doi.org/10.1200/JCO.2021.39.15_SUPPL.TPS7574

@article{facb3206acba4e83ad722734fc0d4991,

title = "Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.",

author = "Mehdi Hamadani and Yuliya Linhares and Mitul Gandhi and Michael Chung and Helena Adamis and David Ungar and Carmelo Carlo-Stella",

note = "TPS7574 Background: Patients (pts) with DLBCL for whom frontline therapy is unsuccessful and who are ineligible for autologous stem cell transplantation have poor outcomes with salvage therapy. Single-agent loncastuximab tesirine (Lonca), an antibody-drug conjugate comprising a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer (PBD) toxin, showed antitumor activity and manageable toxicity in pts with R/R B-cell non-Hodgkin lymphoma in a Phase 1 trial (Hamadani et al.",

year = "2021",

month = may,

day = "20",

doi = "10.1200/JCO.2021.39.15_SUPPL.TPS7574",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.

AU - Hamadani, Mehdi

AU - Linhares, Yuliya

AU - Gandhi, Mitul

AU - Chung, Michael

AU - Adamis, Helena

AU - Ungar, David

AU - Carlo-Stella, Carmelo

N1 - TPS7574 Background: Patients (pts) with DLBCL for whom frontline therapy is unsuccessful and who are ineligible for autologous stem cell transplantation have poor outcomes with salvage therapy. Single-agent loncastuximab tesirine (Lonca), an antibody-drug conjugate comprising a humanized anti-CD19 monoclonal antibody conjugated to a pyrrolobenzodiazepine dimer (PBD) toxin, showed antitumor activity and manageable toxicity in pts with R/R B-cell non-Hodgkin lymphoma in a Phase 1 trial (Hamadani et al.

PY - 2021/5/20

Y1 - 2021/5/20

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.TPS7574

U2 - 10.1200/JCO.2021.39.15_SUPPL.TPS7574

DO - 10.1200/JCO.2021.39.15_SUPPL.TPS7574

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.

Disciplines

Access to Document

Other files and links

Cite this